||ORD 3 1/33P
||EPS - Basic
||Market Cap (m)
|Imperial Innov Daily Update: Imperial Innov is listed in the General Financial sector of the London Stock Exchange with ticker IVO. The last closing price for Imperial Innov was 440p.|
Imperial Innov has a 4 week average price of 434.73p and a 12 week average price of 423.46p.
The 1 year high share price is 516.50p while the 1 year low share price is currently 335p.
There are currently 158,464,520 shares in issue and the average daily traded volume is 7,281 shares. The market capitalisation of Imperial Innov is £681,397,436.
|jambo192: Beaufort note out earlier today: Https://www.research-tree.com/company/GB00B170L953
"This acquisition is a positive step for Cell Medica. Delenex is a clinical stage biopharmaceutical company focussed on developing antibody therapeutics. Last week, Imperial Innovations portfolio company Econic Technologies completed a £5m funding round. The funds would help Econic in progressing with its growth plans. However, last month, Imperial Innovations informed shareholders with a disappointing outcome, following clinical trials undertaken by Circassia Pharmaceuticals in which it has significant investments. The study failed to achieve the desired result, given that both the active treatment and placebo groups were not significantly different. Circassia would now review its full dataset to understand the detailed results and assess whether or not any other confounding factor affected the outcome, as well as the more general impact on its allergy portfolio. Imperial invested £25.5m in Circassia (9.3% stake), the group's largest asset with a net fair value of £77.5m (based on market capitalisation of £833.6m), standing at c.22% of Imperial's net portfolio value of £355.1m as of 31st January 2016. The market reacted negatively to the news, with Circassia's share price falling 67% that day."|
|elgordo: Very downbeat article in the Sunday Times, behind its paywall at
In essence, saying they haven't pulled off any mega-investments (with trebling their investment in Circassia the only biggish win) and as a result share price growth has been barely 3% p.a. over many years.
It's certainly been very quiet for an extended period, hopefully there are a few future unicorns tucked away in the portfolio - full year results out on Wednesday so maybe some useful updates to come.|
|123prezzie: Not a lot of activity here. I am puzzled by the share price which is at a 22% premium to the net asset value of about 225p per share. Most Private Equity outfits trade at a discount of around 40%. Can anyone explain why IVO is so exciting?|
Imperial Innov share price data is direct from the London Stock Exchange